Compare VRDN & VIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRDN | VIRT |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2014 | 2014 |
| Metric | VRDN | VIRT |
|---|---|---|
| Price | $30.42 | $41.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 7 |
| Target Price | $41.17 | ★ $42.71 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 05-25-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | N/A | ★ 72.73 |
| EPS | N/A | ★ 5.13 |
| Revenue | $5,706,000.00 | ★ $3,632,118,000.00 |
| Revenue This Year | $13.90 | N/A |
| Revenue Next Year | $284.55 | $4.02 |
| P/E Ratio | ★ N/A | $7.97 |
| Revenue Growth | N/A | ★ 26.25 |
| 52 Week Low | $9.90 | $31.55 |
| 52 Week High | $34.29 | $45.77 |
| Indicator | VRDN | VIRT |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 58.53 |
| Support Level | $21.50 | $32.61 |
| Resistance Level | $33.71 | $42.08 |
| Average True Range (ATR) | 1.60 | 1.10 |
| MACD | 0.26 | 0.07 |
| Stochastic Oscillator | 92.69 | 65.17 |
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.